Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.35 |
| ▸ | HPGD | P15428 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.32 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.32 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.32 |
| ▸ | KIF11 | P52732 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14297112 | 0.87 | ALDH1A1 (0.46) | ALDH1A1HPGDKDM4ENPSR1HSD17B10 | |
| SCHEMBL16222420 | 0.83 | ALDH1A1 (0.48) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 | |
| SCHEMBL14297093 | 0.79 | ALDH1A1 (0.37) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 | |
| SCHEMBL16219583 | 0.77 | ALDH1A1 (0.34) | ALDH1A1HPGDKDM4ECYP1A2HSD17B10 | |
| SCHEMBL14297119 | 0.77 | KDM4E (0.35) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 | |
| SCHEMBL3263989 | 0.74 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 | |
| SCHEMBL31064790 | 0.74 | ALDH1A1 (0.54) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 | |
| SCHEMBL27904278 | 0.73 | CYP1A2 (0.50) | ALDH1A1HPGDCYP1A2HSD17B10CYP2A6 | |
| SCHEMBL14297092 | 0.72 | CYP1A2 (0.41) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 | |
| SCHEMBL278719 | 0.71 | GPR84 (0.44) | ALDH1A1HPGDKDM4ENPSR1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9771386-B2 | Z-selective ring-closing metathesis reactions | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-09-26 | — | — | US | disclosed |
| US-20170129910-A1 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS | NATIONAL INSTITUTES OF HEALTH, U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES, U.S. GOVERNMENT | 2017-05-11 | — | — | US | disclosed |
| US-9446394-B2 | Z-selective ring-closing metathesis reactions | TRUSTEES OF BOSTON COLLEGE (US) | 2016-09-20 | — | — | US | disclosed |
| US-20150246348-A1 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY | 2015-09-03 | — | — | US | disclosed |
| US-9073801-B2 | Z-selective ring-closing metathesis reactions | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2015-07-07 | — | — | US | disclosed |
| US-20120323000-A1 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS | TRUSTEES OF BOSTON COLLEGE (US) | 2012-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323000-A1 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS | ZYX, ZDHHC7, ZDHHC2 | ALDH1A1 1620/4885HPGD 2362/4885KDM4E 2372/4885 |
| US-20150246348-A1 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS | ZYX, ZDHHC7, ZDHHC2 | ALDH1A1 1620/4885HPGD 2362/4885KDM4E 2372/4885 |
| US-20170129910-A1 | Z-SELECTIVE RING-CLOSING METATHESIS REACTIONS | ZYX, ZDHHC7, ZDHHC2 | ALDH1A1 1620/4885HPGD 2362/4885KDM4E 2372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.